The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Stem Cell Transplantation Benefits Patients with Scleroderma

Stem Cell Transplantation Benefits Patients with Scleroderma

February 26, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists treat more than 100 autoimmune diseases, and most agree that scleroderma is the worst. It disfigures patients and, in doing so, restricts bodily functions and social interactions. It also kills.

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s
Also By This Author
  • Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

In January, Keith M. Sullivan, MD, professor of medicine at Duke University Medical Center in Durham, N.C., and colleagues reported in the New England Journal of Medicine that myeloablative autologous hematopoietic stem cell transplantation resulted in long-term benefits for patients with severe scleroderma.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in the trial, Scleroderma: Cyclophosphamide or Transplantation (SCOT), experienced improved event-free and overall survival. The study randomized patients to receive either stem cell therapy or cyclophosphamide treatment, and demonstrated that patients in the stem cell therapy group had increased cytopenias, but significantly better six-year survival after transplant (86% vs. 51%). The rates of treatment-related death and post-transplantation use of disease-modifying anti-rheumatic drugs (DMARDs) were lower than previous studies of nonmyeloablative transplantation.

Keith M. Sullivan, MD

Inform Patients of the Treatment Option
Dr. Sullivan spoke with The Rheumatologist about the results of the SCOT trial and urged rheumatologists to refer patients with scleroderma and internal organ involvement to a transplant center for consultation. Scleroderma is a rare disease, and diagnosis may be difficult or delayed. “Without an early referral, patients really won’t understand the details of the procedure, the risks and the gains,” he explains.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients whose scleroderma is limited to their skin typically do not experience an increase in mortality. However, one-third of the roughly 300,000 patients with scleroderma in the U.S. experience internal organ involvement, primarily of the lungs, kidneys and/or heart. These patients often progress to organ failure and death. Dr. Sullivan and colleagues are particularly interested in this subset of patients and think the benefits of stem cell treatment outweigh its risks for these patients. Dr. Sullivan suggests rheumatologists identify these patients early in disease via serial pulmonary function testing and CT chest imaging.

A Six-Year Study
The SCOT trial enrolled patients with severe scleroderma who had severe internal organ disease (as opposed to solely skin disease) and treated them with myeloablative therapy followed by CD34+ selected autologous hematopoietic stem cell transplantation. The publication of this research joins two other positive studies, one published in Lancet and the other published in JAMA, that tested nonmyeloablative transplant vs. cyclophosphamide.2,3

“This [research] has been a long-term investment for all my colleagues and NIH,” explains Dr. Sullivan. He emphasizes that the SCOT trial followed all participants for six years, during which the NIH award paid for patients to travel frequently back to their transplant center for assessments, monthly for a year then quarterly through Year 5. The trial demonstrated the durability of the beneficial effects of the stem cell treatment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: clinical trial, Scleroderma, stem cell therapy, stem cell transplantation, Stem Cells

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s
  • Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.